Veracyte(US:VCYT)2025-07-04 07:22Key Financial Results and Guidance - Q3 2024 revenue reached $115.9 million, a 29% year-over-year increase[8] - Testing volumes grew 24% year-over-year to 36,792 tests, with total volume increasing 20% year-over-year to 39,032 tests[8] - The company delivered an adjusted EBITDA margin of 24% for Q3 and 20% year-to-date[8] - Veracyte generated $38 million in cash, including $30 million from operations, resulting in a quarter-end cash balance of $274 million[8] - The company raised its 2024 revenue guidance for the third consecutive quarter to a range of $442 million to $445 million, and year-end cash guidance to $280 million to $285 million[8] Testing Revenue and Volume Growth - Testing revenue demonstrated durable growth, with Q3 2024 reaching $109.5 million[15, 22] - Decipher experienced 36% quarterly volume growth[16] - Afirma showed 12% quarterly volume growth[18] Revenue Guidance and Expectations - The company expects year-over-year testing revenue growth of approximately 28%[29, 31] - Veracyte anticipates high-single-digit growth in 2025 for Afirma[31]